Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $6.8250 (-7.52%) ($6.7900 - $7.5050) on Fri. Sep. 2, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.78% (three month average) | RSI | 35 | Latest Price | $6.8250(-7.52%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 0.1% a day on average for past five trading days. | Weekly Trend | TGTX declines -4.1% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) ARKK(99%) XBI(90%) ARKG(85%) IPO(84%) XLI(84%) | Factors Impacting TGTX price | TGTX will decline at least -3.39% in a week (0% probabilities). OIH(16%) UUP(-61%) USO(-25%) SHY(26%) VCSH(45%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.39% (StdDev 6.78%) | Hourly BBV | -1.2 () | Intraday Trend | 0% | | | |
|
Resistance Level | $7.31 | 5 Day Moving Average | $6.94(-1.66%) | 10 Day Moving Average | $7.01(-2.64%) | 20 Day Moving Average | $7.31(-6.63%) | To recent high | -18.9% | To recent low | 82.7% | Market Cap | $864m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |